Journal of Diabetology (Jan 2023)
Availability of different branded generic vildagliptin after off-patenting: An observation from India
Abstract
Background: Branded generics offer comparable therapeutic benefits at a lower cost, making them essential in healthcare systems worldwide. Vildagliptin, a widely prescribed antidiabetic medication, is available in various branded generic forms. However, limited research has been conducted to assess the availability of these branded generics, particularly in a real-world setting. Methods: A cross-sectional observational study evaluated the availability of branded generics of vildagliptin over 3-month period post 6 months of off-patenting of vildagliptin. Additionally, the switching patterns among patients prescribed branded generic vildagliptin were investigated, shedding light on potential challenges and implications for patient care. Results: Each prescription for branded generic vildagliptin resulted in an average of 2.29 pharmacy visits, highlighting potential challenges in ensuring consistent availability of specific branded generics. Reflecting on switching patterns, due to the unavailability of the prescribed branded generic vildagliptin at the pharmacy store, 28% of patients switched to the innovator brand, 41% switched to other branded generics, and only 31% received the prescribed branded generic. These switching patterns suggest a significant proportion of patients who deviate from the initially prescribed branded generic, potentially impacting treatment adherence and outcomes. Conclusion: Strategies aimed at improving availability and promoting appropriate use of branded generics can enhance the overall quality of care for patients requiring vildagliptin treatment. Further research and interventions should be undertaken to improve coordination between healthcare providers, pharmaceutical companies, and pharmacy stores, aiming to enhance the availability and accessibility of affordable generics without compromising patient care.
Keywords
